We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+2.42%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$940M
AUM Growth
-$233M
Cap. Flow
-$192M
Cap. Flow %
-20.48%
Top 10 Hldgs %
46.78%
Holding
113
New
30
Increased
18
Reduced
25
Closed
32

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$26.6M
2
ELV icon
Elevance Health
ELV
+$26.1M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$16.4M
4
BAX icon
Baxter International
BAX
+$16.3M
5
RDNT icon
RadNet
RDNT
+$14.8M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$30.3M
2
CAH icon
Cardinal Health
CAH
+$29.6M
3
LLY icon
Eli Lilly
LLY
+$29.3M
4
ISRG icon
Intuitive Surgical
ISRG
+$20.9M
5
MRK icon
Merck
MRK
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$28.6B
$118M 12.58%
1,550,000
– –
BSX icon
2
Boston Scientific
BSX
$71.9B
$65.6M 6.98%
650,000
+100,000
+18% +$10.1M
CYTK icon
3
Cytokinetics
CYTK
$10.8B
$44.2M 4.7%
1,100,000
+100,000
+10% +$4.6M
THC icon
4
Tenet Healthcare
THC
$21B
$37M 3.94%
275,000
-125,000
-31% -$16.5M
MLYS icon
5
Mineralys Therapeutics
MLYS
$2.4B
$36.5M 3.89%
2,300,000
+1,425,000
+163% +$16.4M
ELV icon
6
Elevance Health
ELV
$84.5B
$28.3M 3.01%
+65,000
New +$26.1M
NVS icon
7
Novartis
NVS
$293B
$27.9M 2.97%
+250,000
New +$26.6M
VERA icon
8
Vera Therapeutics
VERA
$2.25B
$27.6M 2.94%
1,150,000
– –
EHC icon
9
Encompass Health
EHC
$12.4B
$27.3M 2.91%
270,000
-30,000
-10% -$2.93M
MDT icon
10
Medtronic
MDT
$110B
$27M 2.87%
300,000
+150,000
+100% +$13.4M
GILD icon
11
Gilead Sciences
GILD
$161B
$19.6M 2.09%
175,000
-25,000
-13% -$2.58M
BAX icon
12
Baxter International
BAX
$14.4B
$17.1M 1.82%
+500,000
New +$16.3M
FMS icon
13
Fresenius Medical Care
FMS
$12.9B
$16.9M 1.8%
680,000
+80,000
+13% +$1.9M
NBIX icon
14
Neurocrine Biosciences
NBIX
$16.2B
$16.6M 1.77%
150,000
-10,000
-6% -$1.27M
ASND icon
15
Ascendis Pharma A/S
ASND
$16.4B
$15.6M 1.66%
+100,000
New +$14.3M
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.79B
$14.8M 1.58%
675,000
+125,000
+23% +$3.28M
BTSG icon
17
BrightSpring Health Services
BTSG
$12.2B
$14M 1.49%
775,000
-175,000
-18% -$3.44M
CVS icon
18
CVS Health
CVS
$124B
$13.6M 1.44%
200,000
-300,000
-60% -$18M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$30.3B
$13.5M 1.44%
50,000
+5,000
+11% +$1.28M
QURE icon
20
uniQure
QURE
$3.09B
$13.3M 1.41%
1,250,000
+150,000
+14% +$2.1M
ACLX
21
CALL
DELISTED
Arcellx
ACLX
$13.1M 1.4%
+200,000
New +$13.5M
BPMC
22
DELISTED
Blueprint Medicines
BPMC
$12.8M 1.37%
145,000
-130,000
-47% -$12.7M
ABBV icon
23
AbbVie
ABBV
$429B
$12.6M 1.34%
+60,000
New +$11.7M
RDNT icon
24
RadNet
RDNT
$5.28B
$12.4M 1.32%
+250,000
New +$14.8M
GEHC icon
25
GE HealthCare
GEHC
$31.6B
$12.1M 1.29%
+150,000
New +$12.9M
1
2 3 4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Integral Health Asset Management held 113 positions worth $940M, down 20% from $1.17B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Integral Health Asset Management withdrew a net $192M in Q1 2025, closing 32 positions and reducing 25 holdings. Its most notable exit was Centene, an estimated $30.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier.

Against the trend, Integral Health Asset Management opened a new position in Novartis worth $27.9M.

  • Integral Health Asset Management's largest Q1 2025 buy was Novartis: 250,000 shares worth $27.9M.
  • Integral Health Asset Management added most to Mineralys Therapeutics in Q1 2025, an estimated $16.4M increase.
  • Integral Health Asset Management's biggest Q1 2025 reduction was CVS Health, cutting an estimated $18M.
  • Integral Health Asset Management fully exited Centene in Q1 2025, selling an estimated $30.3M.
  • Integral Health Asset Management's ten largest holdings make up 47% of its $940M portfolio in Q1 2025.
  • Integral Health Asset Management opened 30 new positions and closed 32 in Q1 2025.
  • Integral Health Asset Management's portfolio value fell 20% quarter-over-quarter to $940M.

Based on Integral Health Asset Management's 13F filing for Q1 2025, filed 15 May 2025.